^
Association details:
| Biomarker: | HER-2 underexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | trastuzumab vedotin (MRG002) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer
Published date:
05/26/2022
Excerpt:
The ORR and DCR in 49 evaluable patients were 34.7% and 75.5%, with 17 PR, 20 SD and 12 PD. MRG002 shows promising efficacyand well tolerated in patients with HER2-low breast cancer.
DOI:
10.1200/JCO.2022.40.16_suppl.1102
Trial ID:
